GlassScriptPhysician profile
Melissa Lynne Bernier
NPI 1659772911
$2,534.75
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $229 · 2022: $843 · 2023: $724 · 2024: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,462.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $656.30 | 2021-2024 | Epclusa |
| Abbvie INC. | $632.57 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $246.95 | 2021-2023 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.50 | 2021-2024 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $177.44 | 2022-2024 | Dupixent |
| Janssen Biotech, INC. | $158.44 | 2021-2024 | Stelara, Simponi Aria, Remicade |
| Ardelyx, INC. | $93.29 | 2022-2024 | Ibsrela |
| Qol Medical, LLC | $83.10 | 2023 | Sucraid |
| Pfizer INC. | $37.36 | 2023-2024 | |
| Daiichi Sankyo INC. | $29.43 | 2023 | Injectafer |
| Ironwood Pharmaceuticals, INC | $28.76 | 2024 | |
| Organon LLC | $27.30 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.22 | 2023 | Cyltezo |
| Celgene Corporation | $22.80 | 2024 | Zeposia |
| Genzyme Corporation | $22.77 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $22.56 | 2022 | |
| Apollo Endosurgery US INC | $17.64 | 2023 | Orbera Intragastric Balloon System |
| Merck Sharp & Dohme LLC | $15.88 | 2022 | |
| Novo Nordisk INC | $13.27 | 2021 | |
| Braintree Laboratories, INC. | $11.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Bernier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.